Metoprolol is the most likely culprit for neuropsychiatric symptoms in this patient
Metoprolol, a beta-blocker, is the medication most likely responsible for this patient's fatigue, low mood, slowed thinking, and occasional confusion. Beta-blockers are well-known to cause central nervous system side effects including depression, fatigue, cognitive slowing, and confusion, particularly in older adults.
Why Metoprolol is the Primary Suspect
Beta-blockers, particularly lipophilic agents like metoprolol, readily cross the blood-brain barrier and can cause significant neuropsychiatric effects. The constellation of symptoms described—fatigue, low mood, slowed thinking, and confusion—is classic for beta-blocker-induced CNS depression. While the stroke rehabilitation guidelines 1 emphasize that post-stroke depression affects 25-75% of stroke survivors, medication-induced symptoms must be ruled out first, as they are reversible.
The timing and symptom pattern strongly suggest a medication effect rather than primary post-stroke depression alone. Post-stroke depression typically presents with more prominent mood symptoms and neurovegetative features, whereas this patient's presentation emphasizes cognitive slowing and fatigue alongside mood changes—a pattern more consistent with beta-blocker toxicity.
Why Not the Other Medications
Doxazosin
While doxazosin can cause CNS effects, its primary adverse effects are cardiovascular (postural hypotension, dizziness, syncope) 2. The FDA label specifically warns about postural hypotension and syncope but does not list depression, cognitive slowing, or confusion as prominent features. Drowsiness was reported in only one case of pediatric overdose 2, but neuropsychiatric symptoms are not characteristic adverse effects at therapeutic doses.
Apixaban
Apixaban's adverse effects are predominantly bleeding-related 3. There is no evidence linking apixaban to neuropsychiatric symptoms. Recent studies 4, 5, 6 examining apixaban in stroke patients focus on efficacy and bleeding risk, with no mention of cognitive or mood effects.
Clinical Approach
Immediate action: Consider switching from metoprolol to an alternative antihypertensive agent that does not cross the blood-brain barrier. Options include:
- Hydrophilic beta-blockers (atenolol, nadolol) if beta-blockade is required—these have reduced CNS penetration
- Calcium channel blockers (amlodipine) as per stroke guidelines 7
- ACE inhibitors or ARBs which have shown safety in post-stroke patients 7
The polypharmacy management guidelines 8 specifically identify beta-blockers as medications requiring careful monitoring in older adults, noting their association with cognitive decline and functional impairment through the Drug Burden Index.
Important Caveats
Do not abruptly discontinue metoprolol. The stroke guidelines 7 specifically warn against sudden beta-blocker withdrawal due to risk of rebound hypertension and potential antihypertensive withdrawal syndrome. Taper gradually while monitoring blood pressure.
Assess for concurrent post-stroke depression. The rehabilitation guidelines 1, 9 recommend using structured depression inventories (Patient Health Questionnaire-2) to screen for post-stroke depression, which may coexist with medication effects. However, address the medication issue first—if symptoms persist after medication adjustment, then initiate treatment for post-stroke depression with SSRIs 9, which have Grade A evidence for efficacy.
Monitor for delirium. The cognitive impairment guidelines 10 note that delirium occurs in approximately 25% of stroke patients and should be differentiated from medication effects and post-stroke cognitive impairment. Check electrolytes, assess for infection, and review all medications for anticholinergic burden 8.
Post-Stroke Fatigue Consideration
While post-stroke fatigue affects approximately 50% of survivors 11, the systematic review found insufficient evidence to support specific pharmacological treatments for post-stroke fatigue. This reinforces the importance of eliminating medication-induced fatigue (from metoprolol) before attributing symptoms solely to the stroke itself.